CTO-IVUS: IVUS clinical impact in total occlusions with 2nd generation DES

While the use of intravascular ultrasound (IVUS) during coronary intervention proved useful in multiple studies, there is limited evidence in the literature regarding its use in specifically in chronic total occlusions. The IVUS may help guide in recognizing the true lumen and better distal positioning, better coverage of stent, an optimal apposition and expansion, diagnose dissections, wall hematomas, etc.

This prospective randomized trial and included 402 patients and had as primary end point cardiac death and target vessel revascularization at 12 months. The primary end point occurred in 2.6% of patients in which IVUS was used and 7.1% of guided by angiography group (p = 0.035). The IVUS group used greater pressure post dilatation and scored higher minimum luminal diameters. 

Conclusion 

The IVUS improves outcomes to 12 months in patients with chronic total occlusions treated with 2nd generation stents

1_yang_soojang
Yang-Soo Jang
2014-09-15

Original title: A Prospective, Randomized Trial of Intravascular Ultrasound-Guided Versus Angiography-Guided Drug-Eluting Stent Intervention in Coronary Chronic Total Occlusions.

 

More articles by this author

DKCRUSH-VI: FFR versus conventional angiography in true bifurcations and provisional stent

The aim of this study was to compare angioplasty guided by fractional flow reserve (FFR) versus conventional angiography in bifurcations treated with provisional stent...

OCT-STEMI: Primary angioplasty guided by OCT

This study included 201 patients suffering ST-segment elevation acute coronary syndrome and randomized to the use of optical coherence tomography (OCT) versus conventional angiography...

RIBS IV: Drug-eluting balloon versus everolimus-eluting stent on in-stent restenosis

This prospective, multicenter, randomized trial compared the paclitaxel-eluting balloon versus everolimus-eluting stent to treat patients with in-stent restenosis. 309 patients were included in total...

ABSORB 2: Results at one year of bioabsorbable platform versus Xience

This randomized, controlled, multicenter and blind study compared the second generation of bio-absorbable stent platform with the everolimus-eluting Xience. 501 patients were randomized 2:...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...